Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
131I-cMOv18 IgG
- Development stage
- Unknown
- Lead developer
- National Cancer Institute
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**131I-cMOv18 IgG** is a radiolabeled chimeric monoclonal antibody designed for targeted radioimmunotherapy, primarily developed for ovarian cancer. The antibody, MOv18, specifically targets the folate receptor alpha, which is commonly overexpressed in epithelial ovarian cancers. By labeling this antibody with iodine-131, a beta-emitting radioisotope, the drug selectively delivers cytotoxic radiation to cancer cells via antibody-mediated tumor targeting. 131I-cMOv18 IgG is administered intravenously, and clinical studies suggest it can be safely given to patients with adequate bone marrow reserve and shows therapeutic potential in patients with minimal residual ovarian tumor burden. The agent acts both through antibody targeting and the radiation effect of iodine-131[1][2][3].
- Other names
- 131I-labeled c-MOv18iodine-131-labeled cMOv18 IgGiodine131-labeled cMOv18 IgGiodine 131-labeled cMOv18 IgG
02
Targets
FOLR1 (FRα)
Beyond the preview
Go deeper on 131I-cMOv18 IgG.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 131I-cMOv18 IgG.